As our results suggested that reduced hyperinsulinemia and elevated HOMA-IR index were found in genistein-treated HFD mice, we hypothesized that the hepatic insulin signaling pathway might contribute to the improvement of insulin resistance by genistein administration. The gene discussed is INS; the disease is hyperinsulinism.